Identification of novel mutations associated with clofazimine resistance in Mycobacterium tuberculosis

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 9, 2015, Pages 2507-2510

  Zhang, Shuo ^a   Chen, Jiazhen ^b   Cui, Peng ^b   Shi, Wanliang ^a   Zhang, Wenhong ^b   Zhang, Ying ^a,b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CLOFAZIMINE; BACTERIAL DNA; TUBERCULOSTATIC AGENT;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENOME; BACTERIAL GROWTH; BACTERIUM ISOLATION; BACTERIUM MUTANT; COLONY FORMING UNIT; DNA SEQUENCE; FRAMESHIFT MUTATION; GENE MUTATION; IN VITRO STUDY; INDEL MUTATION; MINIMUM INHIBITORY CONCENTRATION; MUTATION RATE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; START CODON; BACTERIAL GENE; CHEMISTRY; DNA MUTATIONAL ANALYSIS; DRUG EFFECTS; GENETICS; HUMAN; POINT MUTATION;

ANTITUBERCULAR AGENTS; CLOFAZIMINE; DNA MUTATIONAL ANALYSIS; DNA, BACTERIAL; DRUG RESISTANCE, BACTERIAL; GENES, BACTERIAL; GENOME, BACTERIAL; HUMANS; MYCOBACTERIUM TUBERCULOSIS; POINT MUTATION; SEQUENCE ANALYSIS, DNA;

EID: 84945530072     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv150     Document Type: Article

References (19)

1. Barry V, Belton JG, Conalty ML et al. A new series of phenazines (riminocompounds) with high antituberculosis activity. Nature 1957; 179: 1013-5.
2. Browne SG, Hogerzeil LM. "B 663" in the treatment of leprosy. Preliminary report of a pilot trial. Lepr Rev 1962; 33: 6-10.
3. Cholo MC, Steel HC, Fourie PB et al. Clofazimine: current status and future prospects. J Antimicrob Chemother 2012; 67: 290-8.
4. Gopal M, Padayatchi N, Metcalfe JZ et al. Systematic review of clofazimine for the treatment of drug-resistant tuberculosis. Int J Tuberc Lung Dis 2013; 17: 1001-7.
5. Dey T, Brigden G, Cox H et al. Outcomes of clofazimine for the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis. J Antimicrob Chemother 2013; 68: 284-93.
6. Van Deun A, Maug AK, Salim MA et al. Short, highly effective and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010; 182: 684-92.
7. Tyagi S, Ammerman NC, Li SY et al. Clofazimine shortens the duration of the first-line treatment regimen for experimental chemotherapy of tuberculosis. Proc Natl Acad Sci USA 2015; 112: 869-74.
8. Van Rensburg CE, Joone GK, O'Sullivan JF et al. Antimicrobial activities of clofazimine and B669 are mediated by lysophospholipids. Antimicrob Agents Chemother 1992; 36: 2729-35.
9. Yano T, Kassovska-Bratinova S, Teh JS et al. Reduction of clofazimine by mycobacterial type 2 NADH:quinone oxidoreductase: a pathway for the generation of bactericidal levels of reactive oxygen species. J Biol Chem 2011; 286: 10276-87.
10. Hartkoorn RC, Uplekar S, Cole ST. Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2014; 58: 2979-81.
11. Andries K, Villellas C, Coeck N et al. Acquired resistance of Mycobacterium tuberculosis to bedaquiline. PLoS One 2014; 9: e102135.
12. Somoskovi A, Bruderer V, Homke R et al. A mutation associated with clofazimine and bedaquiline cross-resistance in MDR-TB following bedaquiline treatment. Eur Respir J 2015; 45: 554-7.
13. Guo H, Seet Q, Denkin S et al. Molecular characterization of isoniazid-resistant clinical isolates of Mycobacterium tuberculosis from the USA. J Med Microbiol 2006; 55: 1527-31.
14. Zheng H, Lu L, Wang B et al. Genetic basis of virulence attenuation revealed by comparative genomic analysis of Mycobacterium tuberculosis strain H37Ra versus H37Rv. PLoS One 2008; 3: e2375.
15. ZhangS, ChenJ, Shi W et al. Mutations in panD encoding aspartate decarboxylase are associated with pyrazinamide resistance in Mycobacterium tuberculosis. Emerg Microb Infect 2013; 2: e34; doi:10.1038/emi.2013.38.
16. Zhang Y, Mitchison D. The curious characteristics of pyrazinamide: a review. Int J Tuberc Lung Dis 2003; 7: 6-21.
17. Scorpio A, Lindholm-Levy P, Heifets L et al. Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 1997; 41: 540-3.
18. Radhakrishnan A, Kumar N, Wright CC et al. Crystal structure of the transcriptional regulator Rv0678 of Mycobacterium tuberculosis. J Biol Chem 2014; 289: 16526-40.
19. Kozak RA, Alexander DC, Liao R et al. Region of difference 2 contributes to virulence of Mycobacterium tuberculosis. Infect Immun 2011; 79: 59-66.